Study Phase 2

A Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group, 12-week Study to Evaluate the Safety and Tolerability of Macitentan in Subjects With Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH) Due to Left Ventricular Dysfunction

  • 1 CSR Summary Not Yet Available
  • 1 NCT02070991
  • 1 Primary Citation Not Available
  • Data Specification Not Available

Trial Information

Generic NameMacitentanProduct NameOPSUMIT®Therapeutic AreaRespiratory Tract (Lung and Bronchial) DiseasesEnrollment60% Female65.1%% White95.2%
Product ClassEndothelin Receptor AntagonistSponsor Protocol NumberAC-055G201Data PartnerJohnson & JohnsonCondition StudiedHypertension, Pulmonary, ArterialMean/Median Age (Years)71

Supporting Documentation

  • Collected Datasets Available
  • Data Definition Specification Available
  • Protocol with Amendments Available
  • Statistical Analysis Plan Available
  • Clinical Study Report Available

Approved Data Requests Associated with this Trial

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.